Quest Diagnostics Incorporated
DGX
Rangering i aksjer
#914
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Aksjekurs
$238.37
Markedsverdi
$26.31B
Endring (1 dag)
0.71%
Endring (1 år)
29.10%
Land
US
Handel Quest Diagnostics Incorporated (DGX)
Kategori
Healthcare
Inntekter for Quest Diagnostics Incorporated (DGX)
Inntekter i Jun 2026 TTM: $11.56B
Ifølge de nyeste økonomiske rapportene til Quest Diagnostics Incorporated er selskapets nåværende inntekter (TTM) $11.56B. I 2024 hadde selskapet inntekter på $9.87B en økning sammenlignet med inntektene i 2023, som var $9.25B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Quest Diagnostics Incorporated fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $11.56B | 4.76% |
| 2025 | $11.04B | 11.78% |
| 2024 | $9.87B | 6.70% |
| 2023 | $9.25B | -6.38% |
| 2022 | $9.88B | -8.39% |
| 2021 | $10.79B | 14.32% |
| 2020 | $9.44B | 22.15% |
| 2019 | $7.73B | 2.59% |
| 2018 | $7.53B | -2.31% |
| 2017 | $7.71B | 2.58% |
| 2016 | $7.52B | 0.29% |
| 2015 | $7.49B | 0.78% |
| 2014 | $7.44B | 4.04% |
| 2013 | $7.15B | -3.20% |
| 2012 | $7.38B | -1.70% |
| 2011 | $7.51B | 1.92% |
| 2010 | $7.37B | -1.16% |
| 2009 | $7.46B | 2.84% |
| 2008 | $7.25B | 8.12% |
| 2007 | $6.70B | 6.96% |
| 2006 | $6.27B | 13.90% |
| 2005 | $5.50B | 7.36% |
| 2004 | $5.13B | 8.20% |
| 2003 | $4.74B | 15.33% |
| 2002 | $4.11B | 13.24% |
| 2001 | $3.63B | 6.04% |
| 2000 | $3.42B | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $46.34B | 300.83% |
US
|
|
| $25.11B | 117.19% |
US
|
|
| $2.71B | -76.58% |
US
|
|
| - | - |
CN
|
|
| $7.37B | -36.23% |
US
|
